NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (Japon)
DAICO MFG CO., LTD. (Japon)
Inventeur(s)
Kumada, Hiroaki
Kitamura, Naoyuki
Nakamura, Tetsuyuki
Ikeda, Takeshi
Abrégé
The purpose is to prevent the irradiation beam from leaking between the beam irradiation port of the radiation therapy device and the patient affected area that is the target of the emitted irradiation beam, a radiation shielding jig comprising a tare filled with shielding material particles; the tare is made of a resin fabric and has a hollow three-dimensional shape with a radiation pathway portion, the shielding material particles comprising a mixture of sintered particles having a predetermined particle diameter with radiation shielding performance and resin particles having a predetermined particle diameter.
[Problem] To provide a valproic acid derivative for improving the disadvantages or faults associated with using valproic acid itself as medicine. [Solution] Provided is a polymeric compound of valproic acid that is a block copolymer containing a poly(ethylene glycol) segment and a poly(valproic acid vinyl) segment.
C08F 293/00 - Composés macromoléculaires obtenus par polymérisation sur une macromolécule contenant des groupes capables d'amorcer la formation de nouvelles chaînes polymères rattachées exclusivement à une ou aux deux extrémités de la macromolécule de départ
A61K 47/58 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p.ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p.ex. poly[méth]acrylate, polyacrylamide, polystyrène, polyvinylpyrrolidone, alcool polyvinylique ou résine d’acide sulfonique de polystyrène
A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p.ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p.ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p.ex. PEG, PPG, PEO ou polyglycérol
A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p.ex. poudres
To provide a derivative of a short chain fatty acid that can exhibit physiological functions inherent in the short chain fatty acid. [Solution] Provided is a block or graft copolymer including a hydrophobic segment of a repeat unit containing a short chain fatty acid ester that is hydrolyzable by esterase in vivo and a hydrophilic segment including a poly(ethylene glycol) chain. These copolymers are effective in the treatment or therapeutic treatment of various diseases or disorders, including cancer.
C08G 81/02 - Composés macromoléculaires obtenus par l'interréaction de polymères en l'absence de monomères, p.ex. polymères séquencés au moins un des polymères étant obtenu par des réactions ne faisant intervenir que des liaisons non saturées carbone-carbone
4.
CELL DEATH INHIBITOR AND CELL DEATH INHIBITION METHOD
An inhibitor of cell death induced by transient protein expression in a plant, the inhibitor including, as an active ingredient, ascorbic acid or a derivative thereof, a salt thereof, or a solvate thereof, can advantageously inhibit cell death induced by transient protein expression in a plant.
C07K 5/11 - Tétrapeptides la chaîne latérale du premier amino-acide contenant plus de groupes amino que de groupes carboxyle, ou leurs dérivés, p.ex. Lys, Arg
A01G 7/06 - Traitement des arbres ou des plantes en cours de croissance, p.ex. pour prévenir la décomposition du bois, pour teinter les fleurs ou le bois, pour prolonger la vie des plantes
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
The present invention relates to : an activity modulator which is a means for modulating the activity of CD300b-dependent phagocytosis; and medicine for the treatment or prevention of a disease or condition in which the activity is involved. The activity modulator comprises a CD300a-binding substance and modulates CD300b-dependent phagocytosis signals in a macrophage.
A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p.ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénal
A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
A61P 13/12 - Médicaments pour le traitement des troubles du système urinaire des reins
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
6.
PROTEIN EXPRESSION SYSTEM IN PLANT CELL AND USE THEREOF
This expression system comprises: a first nucleic acid fragment including Long Intergenic Region (LIR) derived from a gemini virus, Small Intergenic Region (SIR) derived from a gemini virus, and an expression cassette of a target protein linked between the LIR and the SIR; and a second nucleic acid including an expression cassette of Rep/RepA protein derived from a gemini virus, wherein the expression cassette of the target protein includes a promoter, a nucleic acid fragment coding the target protein, and terminators connected two or more in this order.
A61P 37/06 - Immunosuppresseurs, p.ex. médicaments pour le traitement du rejet de greffe
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C12N 1/15 - Champignons; Leurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C12N 1/19 - Levures; Leurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C12N 1/21 - Bactéries; Leurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p.ex. cellules transformées par des virus
8.
METHOD FOR ISOLATING, REMOVING AND ANALYZING CELLS
The purpose of the present invention is to provide a method for isolating, removing and analyzing cells. Provided is a method for isolating, removing and analyzing cells by filtering a liquid specimen containing cells through a porous polyimide film, and subjecting the cells captured by the film which did not pass through the porous polyimide film, or the cells in the liquid specimen which did pass through the porous polyimide film, to an examination of one or more cell properties selected from a group consisting of cell number or type, internal or external cell structure, type or amount of cell surface antigen, type or amount of material secreted from cells, cell adhesion, and cell survival rate.
C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des micro-organismes viables
C12N 5/078 - Cellules du sang ou du système immunitaire
C12M 1/34 - Mesure ou test par des moyens de mesure ou de détection des conditions du milieu, p.ex. par des compteurs de colonies
C12M 3/06 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus avec des moyens de filtration, d'ultrafiltration, d'osmose inverse ou de dialyse
G01N 1/10 - Dispositifs pour prélever des échantillons à l'état liquide ou fluide
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
A gait training device operates in cooperation with a wearable motion assist device that specifies a walking phase of a wearer, and applies power to the wearer in correspondence to the walking phase of the wearer, the gait training device including: a body weight support device that lifts up the wearer to support a weight applied on feet; a moving unit that is movable according to a walking motion of the wearer; and a control device that controls a moving speed of the moving unit and/or an amount of body-weight support by the body weight support device based upon a position of a center of gravity of the wearer detected by the wearable motion assist device.
A blood flow measuring apparatus includes a sensor unit including a light emitter configured to emit light onto a measurement area and a light receiver configured to receive the light transmitted through the measurement area; at least one more light receiver configured to receive the light transmitted through the measurement area; and a control part configured to measure a blood flow state of the measurement area according to signals outputted by the light receivers. The light emitted by the light emitter is received by the light receivers arranged at different distances from the light emitter and the light receivers output the signals responsive to the received light. The control part measures the blood flow state of the measurement area by performing an arithmetic process to cancel a component of oxygen saturation in the blood, said component being included in the signals outputted by the light receivers.
A61B 5/1455 - Mesure des caractéristiques du sang in vivo, p.ex. de la concentration des gaz dans le sang, de la valeur du pH du sang en utilisant des capteurs optiques, p.ex. des oxymètres à photométrie spectrale
11.
METHOD FOR DETECTING MUSCLE DEGENERATIVE DISEASES, AND METHOD FOR DETERMINING THERAPEUTIC EFFICACY ON THE DISEASES
NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY (Japon)
TAIHO PHARMACEUTICAL CO., LTD. (Japon)
UNIVERSITY OF TSUKUBA (Japon)
Inventeur(s)
Urade, Yoshihiro
Aritake, Kosuke
Maruyama, Toshihiko
Kamauchi, Shinya
Takeda, Shin'Ichi
Nakamura, Akinori
Abrégé
Muscle degenerative diseases can be detected in the early stage and the therapeutic efficacy of a therapeutic agent and/or a therapy method for the diseases can be determined by measuring 11,15-dioxo-9.alpha.-hydroxy-2,3,4,5-tetranorprostan-1,20- dioic acid (referred to as "Tetranor-PGDM", hereinbelow) in a sample isolated from a subject.
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
12.
POLYMERIZED CYCLIC NITROXIDE RADICAL COMPOUND AND USE THEREOF
A method of covalently bonding a cyclic nitroxide radical compound to a hydrophobic block of a specific hydrophylic-phobic block copolymer, and polymerized cyclic nitroxide radical compound copolymerized in this manner, as well as use of such a compound, for instance, in the medical field are provided. The compound demonstrates long term stability in vivo under reductive environment.
C08F 297/00 - Composés macromoléculaires obtenus en polymérisant successivement des systèmes différents de monomère utilisant un catalyseur de type ionique ou du type de coordination sans désactivation du polymère intermédiaire
A61K 31/787 - Polymères contenant de l'azote contenant des hétérocycles ayant l'azote comme hétéro-atome d'un cycle
C08G 65/32 - Polymères modifiés par post-traitement chimique
C08G 85/00 - Procédés généraux pour la préparation des composés prévus dans la présente sous-classe
C09K 15/30 - Compositions anti-oxydantes; Compositions inhibant les modifications chimiques contenant des composés organiques contenant un hétérocycle avec au moins un azote comme membre du cycle
13.
MOTION-ASSIST SYSTEM OF WEARABLE MOTION-ASSIST DEVICE, WEARABLE MOTION-ASSIST DEVICE, AND MOTION-ASSIST METHOD OF WEARABLE MOTION-ASSIST DEVICE
In the present invention, the motion state of the wearable motion-assist device 10-1 of the doctor 1 is sent to the wearable motion-assist device 10-2 of the patient 2 via a network. Then, this motion state is applied to the wearable motion-assist device 10-2 of the patient 2, so that rehabilitation is conducted for the patient 2. Furthermore, the motion state of the wearable motion-assist device 10-2 of the patient 2 is sent from the wearable motion-assist device 10-2 to the wearable motion-assist device 10-1. Then, the motion state of the wearable motion-assist device 10-2 is applied to the wearable motion-assist device 10-1. Accordingly, the doctor 1 can objectively sense the state of the patient 2.
A rehabilitation supporting device 1 includes a first frame 11 arranged along a first skeletal portion extending from a joint, a second frame 12 arranged along a second skeletal portion extending from the joint in a direction different from a direction of the first skeletal portion, an angle sensor 131 arranged to detect a rotational angle position between the first frame and the second frame, a flexion-side biosignal sensor 14 arranged to detect a biosignal of a flexor, an extension-side biosignal sensor 15 arranged to detect a biosignal of an extensor, a calibration unit 31 arranged to determine a flexion-side correction value and an extension-side correction value individually, and a memory unit 34 arranged to store individual correction values of the biosignals different for individuals, the flexion-side correction value, and the extension-side correction value.
An operating status of a motor in a drive unit is analyzed to extend the life of the motor. A wearable motion assistive device 1 includes a shoulder joint mechanism 5 and an elbow joint mechanism 6 for aiding a movement of the shoulder joint and the elbow joint, and a control unit 100 having a control circuit for controlling drive units 11 for the shoulder and elbow joint mechanisms 5 and 6. The control unit 100 controls the drive units 11 based on a physical quantity and a biosignal detected by an angle sensor, a torque sensor, and a biosignal detecting sensor. A controller in the drive unit 11 includes a motor monitoring unit for monitoring an operational status of the motor, and a motor control unit for limiting a drive signal supplied to the motor based on a monitoring result provided by the motor monitoring unit, in order to prevent an overload state of the motor.
A61F 2/70 - Moyens d'actionnement ou de commande électriques
A61F 2/48 - Moyens d'actionnement ou de commande, p.ex. de l'extérieur du corps, commande de sphincters
A61F 2/54 - Bras ou mains artificiels ou leurs parties
A61F 2/60 - Jambes ou pieds artificiels ou leurs parties
A61F 4/00 - Procédés ou dispositifs permettant à des patients ou à des personnes handicapées de commander un appareil ou un dispositif ne faisant pas partie du corps
G01D 5/26 - Moyens mécaniques pour le transfert de la grandeur de sortie d'un organe sensible; Moyens pour convertir la grandeur de sortie d'un organe sensible en une autre variable, lorsque la forme ou la nature de l'organe sensible n'imposent pas un moyen de conversion déterminé; Transducteurs non spécialement adaptés à une variable particulière utilisant des moyens optiques, c. à d. utilisant de la lumière infrarouge, visible ou ultraviolette
G01D 5/28 - Moyens mécaniques pour le transfert de la grandeur de sortie d'un organe sensible; Moyens pour convertir la grandeur de sortie d'un organe sensible en une autre variable, lorsque la forme ou la nature de l'organe sensible n'imposent pas un moyen de conversion déterminé; Transducteurs non spécialement adaptés à une variable particulière utilisant des moyens optiques, c. à d. utilisant de la lumière infrarouge, visible ou ultraviolette avec déviation des rayons lumineux, p.ex. pour une indication optique directe
An operating status of a motor in a drive unit is analyzed to extend the life of the motor. A wearable motion assistive device 1 includes a shoulder joint mechanism 5 and an elbow joint mechanism 6 for aiding a movement of the shoulder joint and the elbow joint, and a control unit 100 having a control circuit for controlling drive units 11 for the shoulder and elbow joint mechanisms 5 and 6. The control unit 100 controls the drive units 11 based on a physical quantity and a biosignal detected by an angle sensor, a torque sensor, and a biosignal detecting sensor. A controller in the drive unit 11 includes a motor monitoring unit for monitoring an operational status of the motor, and a motor control unit for limiting a drive signal supplied to the motor based on a monitoring result provided by the motor monitoring unit, in order to prevent an overload state of the motor.
A61F 2/62 - Jambes ou pieds artificiels ou leurs parties réglables, p.ex. tibias, cuisses ou systèmes squelettiques tubulaires réglables
A61H 1/02 - Appareils d'exercice extenseurs ou de ployage
A61H 3/00 - Appareils pour aider des personnes handicapées à marcher
G01B 11/26 - Dispositions pour la mesure caractérisées par l'utilisation de techniques optiques pour tester l'alignement des axes
G01D 5/30 - Moyens mécaniques pour le transfert de la grandeur de sortie d'un organe sensible; Moyens pour convertir la grandeur de sortie d'un organe sensible en une autre variable, lorsque la forme ou la nature de l'organe sensible n'imposent pas un moyen de conversion déterminé; Transducteurs non spécialement adaptés à une variable particulière utilisant des moyens optiques, c. à d. utilisant de la lumière infrarouge, visible ou ultraviolette avec déviation des rayons lumineux, p.ex. pour une indication optique directe les rayons lumineux étant détectés par des cellules photo-électriques
A motion assistance device has a biological signal detection means for detecting a biological signal from the wearer of the device; a motion assistance device installation member having a drive source for applying torque acting to the wearer by use of each joint of the wearer as a rotating shaft; a control means for controlling the drive source to generate torque corresponding to the biological signal detected by the biological signal detection mean; a drive torque estimation means for estimating the drive torque generated by the drive source; a joint angle detection means for detecting angular displacement of a joint; and a parameter identification means for substituting the drive torque estimated by the drive torque estimation means and the angular displacement detected by the joint angle detection means into an equation of motion to specify the wearer-specific dynamics parameter, the equation relating to the entire system and including wearer-specific dynamics parameter. The control means controls the drive source according to a predetermined control method, based on the equation of motion into which the dynamics parameter identified by the parameter identification means is substituted.
A61H 3/00 - Appareils pour aider des personnes handicapées à marcher
G05B 13/02 - Systèmes de commande adaptatifs, c. à d. systèmes se réglant eux-mêmes automatiquement pour obtenir un rendement optimal suivant un critère prédéterminé électriques
[Problem to be solved] The problem to be solved by the present invention is to reduce the load applied to the wearer by correcting a parameter in correspondence with detectivity of biosignals. [Means to solve problem] The calibration controlling part 162 of the movement assisting apparatus 10 enables the power amplifying part 158 to apply a driving force of the driving source 140 as a load (input torque) from the load generating part 164 to the wearer 12 when the wearer 12 wears the movement assisting wearing device. Then, the wearer 12 applied with the driving force of the driving source 140 generates power from the skeletal muscles by performing a predetermined calibration operation. Accordingly, the physical phenomenon detecting part 142 detects joint angle along with the calibration operation, and the biosignal detecting part 144 detects myoelectric signals. In the parameter correction part 156, a parameter K is corrected based on the difference between the load (input torque) and the driving force (muscular strength) being calculated by the difference deriving part 154 with respect to the phase identified by the phase identifying part 152.
A wearable action-assist device which assists or executes an action of a wearer by substituting for the wearer is provided with an action-assist tool 2 having an actuator 201 which gives power to the wearer 1, a biosignal sensor 221 which detects a wearer's biosignal, a biosignal processing unit 3 which acquires from a biosignal "a" detected by the biosignal sensor a nerve transfer signal "b" for operating a wearer's muscular line skeletal system, and a myoelectricity signal "c" accompanied with a wearer's muscular line activity, an optional control unit 4 which generates a command signal "d" for causing the actuator 201 to generate power according to the wearer's intention using the nerve transfer signal "b" and the myoelectricity signal "c" acquired by the biosignal processing unit 3, and a driving current generating unit 5 which generates a current according to the nerve transfer signal b and a current according to the myoelectricity signal "c", respectively, based on the command signal "d" generated by the optional control unit 4, and supplies the currents to the actuator 201.
brevets
